Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Steve van Os"'
Autor:
Carol M. MacLean, Albertas Ulys, Feliksas Jankevičius, Žilvinas Saladžinskas, Steve van Os, Finn Larsen
Publikováno v:
Medicina, Vol 59, Iss 4, p 681 (2023)
Background and objectives: Teverelix drug product (DP) is a gonadotropin-releasing hormone antagonist in development for the treatment of patients with prostate cancer in whom androgen deprivation therapy is indicated. The aim of this paper is to pre
Externí odkaz:
https://doaj.org/article/dd49169410294d96a4011eed9550ca51
Autor:
Teresa Parli, Anthony M. Joshua, Brad Rosbrook, Ping Lin, Andrew J. Armstrong, Celestia S. Higano, Fred Saad, Steve van Os, Tomasz M. Beer, Bertrand Tombal
Publikováno v:
European Urology, Vol. 78, no. 3, p. 347-357 (2020)
In the PREVAIL study, enzalutamide significantly improved clinical outcomes versus placebo in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). To evaluate long-term benefits and risks of enzalutamide in the f
Autor:
Laurence Klotz, Fong Wang, D. Robert Siemens, Ping Lin, Arnauld Villers, Steve van Os, Benoit Baron, Nahla Hasabou, Simon Chowdhury, Neal D. Shore, Axel Heidenreich
Publikováno v:
Journal of Urology. 199:147-154
Enzalutamide significantly prolonged median progression-free survival vs bicalutamide in chemotherapy naïve men with metastatic castration resistant prostate cancer in the TERRAIN (Enzalutamide versus Bicalutamide in Castrate Men with Metastatic Pro
Autor:
Christopher P. Evans, Ad Theeuwes, Bertrand Tombal, Fred Saad, Peter F.A. Mulders, Steve van Os, Teuvo L.J. Tammela, Go Kimura, Celestia S. Higano, Anders Bjartell, Kurt Miller, Michael Borre, Tomasz M. Beer, Suha Sari, Peter Iversen, Cora N. Sternberg, Andrew J. Armstrong, Dana E. Rathkopf, Choung Soo Kim, Yohann Loriot, Teresa Parli
Publikováno v:
European urology, vol 71, iss 2
Beer, T M, Armstrong, A J, Rathkopf, D, Loriot, Y, Sternberg, C N, Higano, C S, Iversen, P, Evans, C P, Kim, C-S, Kimura, G, Miller, K, Saad, F, Bjartell, A S, Borre, M, Mulders, P, Tammela, T L, Parli, T, Sari, S, van Os, S, Theeuwes, A & Tombal, B 2017, ' Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer : Extended Analysis of the Phase 3 PREVAIL Study ', European Urology, vol. 71, no. 2, pp. 151-154 . https://doi.org/10.1016/j.eururo.2016.07.032
European Urology, 71, 2, pp. 151-154
European Urology, 71, 151-154
Beer, T M, Armstrong, A J, Rathkopf, D, Loriot, Y, Sternberg, C N, Higano, C S, Iversen, P, Evans, C P, Kim, C-S, Kimura, G, Miller, K, Saad, F, Bjartell, A S, Borre, M, Mulders, P, Tammela, T L, Parli, T, Sari, S, van Os, S, Theeuwes, A & Tombal, B 2017, ' Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer : Extended Analysis of the Phase 3 PREVAIL Study ', European Urology, vol. 71, no. 2, pp. 151-154 . https://doi.org/10.1016/j.eururo.2016.07.032
European Urology, 71, 2, pp. 151-154
European Urology, 71, 151-154
Contains fulltext : 173185.pdf (Publisher’s version ) (Closed access) Enzalutamide significantly improved radiographic progression-free survival (rPFS) and overall survival (OS) among men with chemotherapy-naive metastatic castration-resistant pros
Publikováno v:
Annals of the New York Academy of Sciences. 1358:13-27
Prostate cancer is the most prevalent cancer among men in the Western world and a leading cause of cancer-related death among men. Within 5 years of initial diagnosis, approximately 10-20% of men will progress to metastatic castration-resistant prost
Autor:
Nahla Hasabou, Simon Chowdhury, Steve van Os, Suman Bhattacharya, Arnauld Villers, Axel Heidenreich, Laurence Klotz, Neal D. Shore, Fong Wang, De Phung, D. Robert Siemens
Publikováno v:
The Lancet. Oncology. 17(2)
Enzalutamide is an oral androgen-receptor inhibitor that has been shown to improve survival in two placebo-controlled phase 3 trials, and is approved for patients with metastatic castration-resistant prostate cancer. The objective of the TERRAIN stud
Autor:
Peter, Kenemans, Nigel J, Bundred, Jean-Michel, Foidart, Ernst, Kubista, Bo, von Schoultz, Piero, Sismondi, Rena, Vassilopoulou-Sellin, Cheng Har, Yip, Jan, Egberts, Mirjam, Mol-Arts, Roel, Mulder, Steve, van Os, Matthias W, Beckmann, J, Pitkin
Publikováno v:
Lancet Oncology, 10(2), 135-146. Lancet Publishing Group
Kenemans, P, Bundred, N J, Foidart, J M, Kubista, E, von Schoultz, B, Sismondi, P, Vassilopoulou-Sellin, R, Yip, C H, Egberts, J C, Mol-Arts, M, Mulder, R, van Os, S & Beckmann, M W 2009, ' Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial ', Lancet Oncology, vol. 10, no. 2, pp. 135-146 . https://doi.org/10.1016/S1470-2045(08)70341-3
The lancet oncology
Kenemans, P, Bundred, N J, Foidart, J M, Kubista, E, von Schoultz, B, Sismondi, P, Vassilopoulou-Sellin, R, Yip, C H, Egberts, J C, Mol-Arts, M, Mulder, R, van Os, S & Beckmann, M W 2009, ' Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial ', Lancet Oncology, vol. 10, no. 2, pp. 135-146 . https://doi.org/10.1016/S1470-2045(08)70341-3
The lancet oncology
Summary Background Vasomotor symptoms and bone loss are complications frequently induced by adjuvant treatment for breast cancer. Tibolone prevents both side-effects, but its effect on cancer recurrence is unknown. The aim of this study was to show n
Autor:
David Forer, Axel Heidenreich, Fong Wang, Steve van Os, Simon Chowdhury, Robert Siemens, Laurence Klotz, Maha Hussain, Arnauld Villers, Benoit Baron, Lawrence Karsh, Neal D. Shore
Publikováno v:
Journal of Urology. 193
Autor:
Benoit Baron, Neal D. Shore, David Forer, D. Robert Siemens, Nahla Hasabou, Axel Heidenreich, Steve van Os, Laurence Klotz, Simon Chowdhury, Fong Wang, Arnauld Villers
Publikováno v:
Journal of Clinical Oncology. 34:5063-5063
5063Background: In the TERRAIN trial (NCT01288911), enzalutamide (ENZA) significantly increased progression-free survival (PFS) compared to bicalutamide (BIC) in patients (pts) with progressive met...
OBJECTIVE:: More than 50% of all fractures occur in people without osteoporosis. Hormone therapy increases bone density, improves postural balance, and reduces fracture risk in postmenopausal women. It is unclear whether tibolone, a synthetic steroid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e742709cc57cdb9e833f8121df0ac0e3
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-129577
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-129577